- Catalent Inc (NYSE: CTLT) reported Q4 FY22 sales of $1.31 billion, +10% Y/Y as reported, or 15% in constant currency, slightly missing the consensus of $1.33 billion.
- Fiscal sales reached $4.83 billion, in line with the management guidance of $4.8 billion - $4.9 billion.
- Adjusted EPS of $1.19, compared to $1.16 last year, surpassed the consensus of $1.15.
- Adjusted EBITDA was $384 million, or a margin of 29%, compared to $348 million a year ago.
- Biologics segment sales increased 14% to $667 million.
- "Our past fiscal year saw record performance and growth for Catalent, due in part to a series of significant investments in production capacity at drug manufacturing facilities in both North America and Europe over the last several years to help us meet needs across high-growth areas of customer demand," said Alessandro Maselli, President & CEO.
- Related: Catalent-Repligen Merger 'Seems Unlikely,' This Analyst Says.
- Softgel and Oral Technologies segment revenues of $350 million were up 22%.
- The Oral and Specialty Delivery segment's sales were $194 million, up 11%.
- Clinical Supply Services segment revenues improved by 4% to $104 million.
- Guidance: For FY23, Catalent expects $4.975-$5.225 billion in revenue compared to the consensus of $5.26 billion.
- It expects adjusted EBITDA of $1.31-$1.390 billion and adjusted net income of $660-$730 million.
- Price Action: CTLT shares are down 8.15% at $91.58 on the last check Monday.
Read at Benzinga